Database : MEDLINE
Search on : Paraneoplastic and Endocrine and Syndromes [Words]
References found : 1553 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 156 go to page                         

  1 / 1553 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29464446
[Au] Autor:Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
[Ad] Address:Department of Internal Medicine IV, University-Hospital Campus Grosshadern, Ludwig-Maximilian University of Munich, Munich, Germany.
[Ti] Title:Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
[So] Source:Rev Endocr Metab Disord;, 2018 Feb 20.
[Is] ISSN:1573-2606
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies that can develop in various organs. A significant number of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is functionally active and presents with symptoms related to the secretion of biologically active substances, leading to the development of distinct clinical syndromes. There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. Specific supportive therapy of patients with NETs includes management or prevention of hormone-related clinical syndromes and paraneoplastic states. Supportive therapy plays a key role in NET treatment. Supportive therapy includes debulking surgery and interventional radiologic techniques to reduce tumour bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. Supportive therapies are a type of of comprehensive treatment addressing the patient as a whole person throughout the process of NET treatment. Therefore, supportive therapy also encompasses psychosocial support, expert nursing, nutritional support and management of cancer related pain.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:Publisher
[do] DOI:10.1007/s11154-018-9443-6

  2 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29387897
[Au] Autor:Reisch N; Reincke M
[Ad] Address:Medizinische Klinik IV, Klinikum der Universität München, Ziemssenstr. 1, 80336, München, Deutschland. nicole.reisch@med.uni-muenchen.de.
[Ti] Title:Endokrine paraneoplastische Syndrome. [Endocrine paraneoplastic syndromes].
[So] Source:Internist (Berl);59(2):125-133, 2018 Feb.
[Is] ISSN:1432-1289
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:Endocrine paraneoplastic syndromes result from the production of bioactive substances from neoplastic cells, of endocrine or neuroendocrine origin. Typically these are located in the lungs, the gastrointestinal tract, pancreas, thyroid gland, adrenal medulla, skin, prostate or breast. In endocrine paraneoplastic syndromes the secretion of peptides, amines or other bioactive substances is always ectopic and not related to the anatomical source. The clinical presentation, however, is indistinguishable from a suspected eutopic endocrine tumor posing a diagnostic challenge. The most common endocrine paraneoplastic syndromes are based on the secretion of antidiuretic hormone (ADH) resulting in hyponatremia, secretion of adrenocorticotropic hormone (ACTH) or rarely corticotropin-releasing hormone (CRH) resulting in Cushing syndrome as well as secretion of growth hormone-releasing hormone resulting in acromegaly. Paraneoplastic endocrine syndromes mainly occur in highly malignant tumors; however, the development of these tumors does not necessarily correlate with tumor stage, malignant potential or prognosis. As endocrine paraneoplastic syndromes are a rare complication, there are hardly any evidence-based therapeutic recommendations. Treatment of the underlying tumor is the first choice and in a palliative setting symptomatic therapy is possible.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180211
[Lr] Last revision date:180211
[St] Status:In-Data-Review
[do] DOI:10.1007/s00108-017-0377-y

  3 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29093239
[Au] Autor:Darmawan G; Wijaya I; Hamijoyo L; Fadjari TH
[Ad] Address:Department of Internal Medicine, Faculty of Medicine, University of Padjadjaran - Hasan Sadikin Hospital, Bandung, Indonesia. guntur_d@yahoo.com.
[Ti] Title:Paraneoplastic Arthritis in a Patient with Non-Hodgkin's Lymphoma.
[So] Source:Acta Med Indones;49(3):267-269, 2017 Jul.
[Is] ISSN:0125-9326
[Cp] Country of publication:Indonesia
[La] Language:eng
[Ab] Abstract:Paraneoplastic syndromes are a group of disorders associated with benign or malignant tumors but not related to mass effect or invasion directly. Paraneoplastic syndromes may affect any organic system of the human body, such as endocrine, neurologic, dermatologic, hematologic, rheumatologic. Paraneoplastic rheumatic syndromes are not quite common, about 7-10% of paraneoplastic syndromes, and may mimic rheumatic diseases. We present an interesting case of paraneoplastic arthritis in a woman with non-Hodgkin's lymphoma.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[St] Status:In-Process

  4 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28655412
[Au] Autor:Viau M; Renaud MC; Grégoire J; Sebastianelli A; Plante M
[Ad] Address:Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire de Québec, Université Laval 2705 boulevard Laurier, Québec City, Québec G1V 4G2, Canada. Electronic address: Mathieu.Viau.1@ULaval.ca.
[Ti] Title:Paraneoplastic syndromes associated with gynecological cancers: A systematic review.
[So] Source:Gynecol Oncol;146(3):661-671, 2017 Sep.
[Is] ISSN:1095-6859
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A number of paraneoplastic syndromes have been described with gynecological cancers. These syndromes are induced by substances secreted by the tumor or by an immune response triggered by the cancer. Each system of the human body can be affected by different syndromes. Indeed, paraneoplastic syndromes occurring from tumors of the gynecologic tract were found to involve the nervous, ophthalmologic, dermatologic, rheumatologic, endocrine, hematologic and renal systems. These syndromes can manifest before, at the time, or after the diagnosis of cancer. They can also occur at the time of a recurrence. Knowledge about these syndromes is important for physicians caring for patients with cancers, as they can result in severe morbidity and must be treated appropriately. Literature regarding paraneoplastic syndromes associated with tumors of the female genital tract is scattered and the subject has not been reviewed recently. A systematic literature search was thus conducted to identify paraneoplastic syndromes associated with gynecologic cancers. This review focuses on the cancers involved with each paraneoplastic syndrome, and on their pathophysiology, clinical manifestations, possible complications, outcomes, and treatments. As the mainstay of treatment in these conditions is often to address the underlying tumor, it is of upmost importance that physicians be aware of these rare cancer manifestations.
[Mh] MeSH terms primary: Genital Neoplasms, Female/complications
Hematologic Diseases/etiology
Paraneoplastic Syndromes/etiology
Skin Diseases/etiology
[Mh] MeSH terms secundary: Female
Humans
Kidney Diseases/etiology
Paraneoplastic Endocrine Syndromes/etiology
Paraneoplastic Syndromes, Nervous System/etiology
Paraneoplastic Syndromes, Ocular/etiology
Rheumatic Diseases/etiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1709
[Cu] Class update date: 170919
[Lr] Last revision date:170919
[Js] Journal subset:IM
[Da] Date of entry for processing:170629
[St] Status:MEDLINE

  5 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28343156
[Au] Autor:Verma R; Lambert A; Katz HH; Benson SJ
[Ad] Address:Hospitalist, Department of Hospital Medicine, Augusta Health, Fishersville, Virginia, USA.
[Ti] Title:Ectopic ACTH-producing large cell neuroendocrine Pancoast tumour presenting as Horner syndrome.
[So] Source:BMJ Case Rep;2017, 2017 Mar 24.
[Is] ISSN:1757-790X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:We present an interesting case where a patient is presented with a droopy left eyelid (as part of Horner syndrome) and Cushingoid features which were a result of a Pancoast tumour (apical lung tumour in superior pulmonary sulcus) involving the left lung. This tumour was secreting ectopic adrenocorticotropic hormone (ACTH), a paraneoplastic endocrine phenomenon, which resulted in Cushing syndrome symptomatology. Though most ectopic ACTH-producing lung cancers are either small cell or carcinoid tumours, this was in fact a large cell neuroendocrine cancer (LCNEC). Patient underwent surgical resection and adjuvant/neoadjuvant chemotherapy with radiation; however, he succumbed to LCNEC given aggressive nature of the disease.
[Mh] MeSH terms primary: ACTH Syndrome, Ectopic/diagnosis
Carcinoma, Large Cell/complications
Horner Syndrome
Pancoast Syndrome
[Mh] MeSH terms secundary: ACTH Syndrome, Ectopic/etiology
Adrenocorticotropic Hormone
Carcinoid Tumor/complications
Carcinoid Tumor/secretion
Carcinoid Tumor/surgery
Carcinoma, Large Cell/secretion
Fatigue/etiology
Humans
Lung Neoplasms/diagnosis
Lung Neoplasms/secretion
Male
Neoadjuvant Therapy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:9002-60-2 (Adrenocorticotropic Hormone)
[Em] Entry month:1705
[Cu] Class update date: 170516
[Lr] Last revision date:170516
[Js] Journal subset:IM
[Da] Date of entry for processing:170327
[St] Status:MEDLINE

  6 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28341725
[Au] Autor:Dimitriadis GK; Angelousi A; Weickert MO; Randeva HS; Kaltsas G; Grossman A
[Ad] Address:The Arden NET CoEWarwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UK g.dimitriadis@warwick.ac.uk.
[Ti] Title:Paraneoplastic endocrine syndromes.
[So] Source:Endocr Relat Cancer;24(6):R173-R190, 2017 Jun.
[Is] ISSN:1479-6821
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The majority of neoplasms are responsible for symptoms caused by mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic syndromes when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Endocrine paraneoplastic syndromes can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. These syndromes can precede, occur concomitantly or present at a later stage of tumour development, and along with the secreted substances constitute the biological 'fingerprint' of the tumour. Their detection can facilitate early diagnosis of the underlying neoplasia, monitor response to treatment and/or detect early recurrences following successful initial management. Although when associated with tumours of low malignant potential they usually do not affect long-term outcome, in cases of highly malignant tumours, endocrine paraneoplastic syndromes are usually associated with poorer survival outcomes. Recent medical advances have not only improved our understanding of paraneoplastic syndrome pathogenesis in general but also enhanced their diagnosis and treatment. Yet, given the rarity of endocrine paraneoplastic syndromes, there is a paucity of prospective clinical trials to guide management. The development of well-designed prospective multicentre trials remains a priority in the field in order to fully characterise these syndromes and provide evidence-based diagnostic and therapeutic protocols.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1703
[Cu] Class update date: 170506
[Lr] Last revision date:170506
[St] Status:In-Process
[do] DOI:10.1530/ERC-17-0036

  7 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28217682
[Au] Autor:Kwon DY; Han GH; Ulak R; Ki KD; Lee JM; Lee SK
[Ad] Address:Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
[Ti] Title:Syndrome of inappropriate antidiuretic hormone secretion following irinotecan-cisplatin administration as a treatment for recurrent ovarian clear cell carcinoma.
[So] Source:Obstet Gynecol Sci;60(1):115-117, 2017 Jan.
[Is] ISSN:2287-8572
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:Syndrome of inappropriate antidiuretic hormone secretion (SIADH) has various causes including central nervous system disorders, pulmonary and endocrine diseases, paraneoplastic syndromes, and use of certain drugs. SIADH induced by chemotherapy with irinotecan-cisplatin is not a common complication. Here, we review a case of SIADH after treatment with irinotecan-cisplatin. A 45-year-old woman received adjuvant chemotherapy (paclitaxel-carboplatin) for ovarian clear cell carcinoma, but the cancer recurred within 9 months of chemotherapy. Subsequently, a second line of combination chemotherapy containing irinotecan-cisplatin was initiated. However, 5 days after chemotherapy administration, her general condition began to deteriorate; her hematological tests revealed hyponatremia. Therefore, it is imperative to consider the possibility of SIADH in patients being treated with irinotecan-cisplatin-based chemotherapy. Proper monitoring of serum sodium levels and assessment of clinical symptoms should be performed in such patients for early diagnosis and prompt management.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1702
[Cu] Class update date: 170816
[Lr] Last revision date:170816
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5468/ogs.2017.60.1.115

  8 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28160197
[Au] Autor:Zalatnai A; Perjési E; Galambos E
[Ad] Address:First Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, H-1085 Ülloi út 26, Budapest, Hungary. zalatnai@korb1.sote.hu.
[Ti] Title:Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes.
[So] Source:Pathol Oncol Res;, 2017 Feb 03.
[Is] ISSN:1532-2807
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:When 150 years ago Armand Trousseau proposed that some thrombotic events might be the first sign of concealed visceral malignancies, these findings seemed to be just of anecdotal interest. Since then, however, we have learned that adenocarcinomas, including pancreatic cancers could be associated with a wide spectrum of paraneoplastic syndromes. They may precede the detection of the tumor, may occur simultaneously or may develop during its progression. Due to various hematologic, endocrine, cutaneous, articular, neuromuscular, renal or even psychiatric syndromes, their correct interpretation is intriguing, and because their early signs are not necessarily recognized first by oncologists, the paraneoplastic syndromes pose a diagnostic challenge. Unfortunately, we cannot generalize about their mechanisms, because the molecular backgrounds are far-reaching. In most of the cases, the pancreatic cancer cells release various factors into the bloodstream triggering the coagulation cascade. These patients frequently present with venous thromboembolism, and sometimes they are resistant to anticoagulation. The simultaneous thrombotic and bleeding evens do reflect the abnormal hemostasis. In other instances autoantibodies are formed against cutaneous, renal, neuromuscular or nervous tissues, but the mechanism of some syndromes remains unclear. Clinicians should be aware that pancreatic carcinoma may be associated with not just the Trousseau-syndrome.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1702
[Cu] Class update date: 170204
[Lr] Last revision date:170204
[St] Status:Publisher
[do] DOI:10.1007/s12253-017-0206-6

  9 / 1553 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 28057913
[Au] Autor:Motilal Nehru V; Garcia G; Ding J; Kong F; Dai Q
[Ad] Address:Department of Medicine, Staten Island University Hospital, Staten Island, NY, USA.
[Ti] Title:Humoral Hypercalcemia in Uterine Cancers: A Case Report and Literature Review.
[So] Source:Am J Case Rep;18:22-25, 2017 Jan 06.
[Is] ISSN:1941-5923
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND Paraneoplastic hypercalcemia is a well-described complication associated with a variety of malignancies. However, its incidence in gynecological malignancies is low. CASE REPORT A 53-year-old woman presented with progressive abdominal distention and irregular vaginal bleeding of several weeks' duration. A contrast CT abdomen and pelvis was significant for a mass in the lower uterine/cervical region, multiple peritoneal and omental masses, enlarged pelvic and paraaortic lymph nodes, and large-volume ascites. A pelvic exam revealed a fungating vaginal mass, with biopsy showing a high-grade tumor with immunohistochemical staining positive for vimentin, CD10, and cyclin D1, consistent with endometrial stromal sarcoma. During her hospitalization, the patient became increasingly lethargic. Workup showed severe hypercalcemia and evidence of acute kidney injury. The patient did not have evidence of bony metastatic disease on imaging studies. Further laboratory evaluation revealed an elevated PTHrP of 301 pg/mL (nl 14-27), a depressed PTH level of 3 pg/mL (nl 15-65), and a depressed 25-OH vitamin D level of 16 ng/mL (nl 30-100), consistent with humoral hypercalcemia of malignancy. The patient was treated with pamidronate, calcitonin, and intravenous fluids. She eventually required temporary hemodialysis and denosumab for refractory hypercalcemia, which improved her electrolyte abnormalities and clinical status. CONCLUSIONS Uterine malignancies of various histologies are increasingly recognized as a cause of humoral hypercalcemia. They are an important differential diagnosis in a woman with hypercalcemia and abnormal vaginal bleeding or abdominal symptoms.
[Mh] MeSH terms primary: Biomarkers, Tumor/blood
Hypercalcemia/diagnosis
Hypercalcemia/etiology
Paraneoplastic Endocrine Syndromes/complications
Paraneoplastic Endocrine Syndromes/diagnosis
Parathyroid Hormone-Related Protein/blood
Uterine Neoplasms/complications
Uterine Neoplasms/diagnosis
[Mh] MeSH terms secundary: Chemotherapy, Adjuvant/methods
Diagnosis, Differential
Endometrial Neoplasms/complications
Fatal Outcome
Female
Humans
Hypercalcemia/blood
Hypercalcemia/therapy
Middle Aged
Neoadjuvant Therapy/methods
Neoplasm Staging
Paraneoplastic Endocrine Syndromes/blood
Paraneoplastic Endocrine Syndromes/therapy
Parathyroid Hormone/blood
Parathyroid Hormone-Related Protein/secretion
Radiotherapy, Adjuvant/methods
Risk Factors
Sarcoma, Endometrial Stromal/complications
Time Factors
Uterine Neoplasms/blood
Uterine Neoplasms/therapy
Vitamin D/blood
Vitamins/blood
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (Parathyroid Hormone); 0 (Parathyroid Hormone-Related Protein); 0 (Vitamins); 1406-16-2 (Vitamin D)
[Em] Entry month:1703
[Cu] Class update date: 170324
[Lr] Last revision date:170324
[Js] Journal subset:IM
[Da] Date of entry for processing:170107
[St] Status:MEDLINE

  10 / 1553 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 27820136
[Au] Autor:Grimes A; Mirkheshti N; Chatterjee B; Tomlinson G; Assanasen C
[Ad] Address:Departments of *Pediatrics, Hematology/Oncology ‡Molecular Medicine, UT Health Science Center San Antonio †Greehey Children's Cancer Research Institute §Texas Research Park, San Antonio, TX ∥Dept of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD.
[Ti] Title:Paraneoplastic Galactorrhea in Childhood T-ALL: An Evaluation of Tumor-derived Prolactin.
[So] Source:J Pediatr Hematol Oncol;39(1):e18-e20, 2017 Jan.
[Is] ISSN:1536-3678
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:T-cell acute lymphoblastic leukemia (T-ALL) comprises 15% of childhood leukemia. Although multiagent pulse chemotherapy has improved event-free survival in recent decades, the lack of reliable prognosticators and high rate of relapse remain a challenge. Described is a novel discovery of tumor-derived hyperprolactinemia in childhood T-ALL through a case associated with paraneoplastic galactorrhea. Prolactin production by tumor cells, although a rare phenomenon, is previously demonstrated in several adult cancers and 2 pediatric malignancies with unknown implications. This is the first report demonstrating tumor-derived prolactin in pediatric T-ALL and offers potential as a disease marker and therapeutic drug target.
[Mh] MeSH terms primary: Galactorrhea/etiology
Paraneoplastic Endocrine Syndromes/etiology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/complications
Prolactin/blood
[Mh] MeSH terms secundary: Adolescent
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Arthralgia/etiology
Asparaginase/administration & dosage
Chromosome Deletion
Doxorubicin/administration & dosage
Fatigue/etiology
Female
Galactorrhea/blood
Gene Deletion
Humans
Paraneoplastic Endocrine Syndromes/blood
Polyethylene Glycols/administration & dosage
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Prednisone/administration & dosage
Proto-Oncogene Proteins c-ets/genetics
Remission Induction
Repressor Proteins/genetics
Vincristine/administration & dosage
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (ETS translocation variant 6 protein); 0 (Proto-Oncogene Proteins c-ets); 0 (Repressor Proteins); 30IQX730WE (Polyethylene Glycols); 5J49Q6B70F (Vincristine); 7D96IR0PPM (pegaspargase); 80168379AG (Doxorubicin); 9002-62-4 (Prolactin); EC 3.5.1.1 (Asparaginase); VB0R961HZT (Prednisone)
[Em] Entry month:1709
[Cu] Class update date: 170904
[Lr] Last revision date:170904
[Js] Journal subset:IM
[Da] Date of entry for processing:161108
[St] Status:MEDLINE


page 1 of 156 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information